Pharmaceuticals, Biotechnology and Life Sciences
Biohaven Pharmaceutical started a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer’s disease (AD).
Second Genome has dosed first patient in a Phase 2 test of its oral, small molecule inhibitor of P2X7, called SGM-1019, for treating nonalcoholic steatohepatitis (NASH).
Alvotech has raised $300 million through a private bond offering to fuel continued growth, refinance of existing debt and the further development of Alvotech’s biosimilar assets.
Wren Therapeutics has cashed in £18 million from an international syndicate led by The Baupost Group, in a Series A financing round, which also included LifeForce Capital and a number of high net worth individual investors, the company said Tuesday.
TWi Biotechnology has enrolled patients in its Phase 2 clinical trial of AC-203 for the treatment of inherited Epidermolysis Bullosa (EB).
Oramed Pharmaceuticals has started recruiting patients for its first study of
oral GLP-1 capsule ORMD-0901 under Oramed’s existing FDA Investigational New Drug application (IND), in Phase 1 (PK) pharmacokinetic study.
Vertex Pharmaceuticals Limitedgot will extend label for its cystic fibrosis children patients treatment Orkambi in Europe, after the Union’s Commissions’ approval.
Taisho Pharmaceutical Holdings has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion, Bristol-Myers Squibb said in a statement on Saturday.
The UK market focused joint venture between Canopy Growth Corporation and Beckley Canopy Therapeutics will exclusively distribute Cannabis medicinal products of newly formed, built-for-purpose distribution company that will introduce Spectrum Cannabis medicinal cannabis products to UK patients and doctors.
Redx got back on track to resume clinical evaluation of RXC004 in patients with advanced solid tumours in the first half of 2019.